(:PLXP)

Apr 12, 2023 05:24 pm ET
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin...
Apr 11, 2023 04:28 pm ET
PLx Pharma Inc. Receives Nasdaq Delisting Notice
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Nov 10, 2022 05:00 pm ET
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Oct 26, 2022 09:00 am ET
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Sep 12, 2022 04:30 pm ET
Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Aug 12, 2022 07:00 am ET
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Aug 12, 2022 06:50 am ET
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Jul 27, 2022 08:30 am ET
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Jun 01, 2022 08:30 am ET
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
May 20, 2022 08:30 am ET
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
May 13, 2022 06:50 am ET
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Apr 22, 2022 06:50 am ET
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Mar 11, 2022 06:50 am ET
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Mar 01, 2022 06:50 am ET
PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Feb 22, 2022 04:30 pm ET
PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Feb 03, 2022 04:30 pm ET
PLx Pharma Inc. Proudly Celebrates Go Red for Women Day® 2022 to Support Heart Health Awareness
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Jan 19, 2022 06:50 am ET
PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Nov 22, 2021 09:15 am ET
PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many...
Nov 12, 2021 06:50 am ET
PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update
-- Early feedback received from consumers and healthcare professionals is very positive -– SPARTA, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) --  PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform...
Nov 04, 2021 09:50 am ET
PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin Capsules
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuardTM drug delivery platform that has the potential to improve the absorption of many drugs...
Nov 01, 2021 04:30 pm ET
PLx Pharma Inc. to Discuss 2021 Third Quarter Financial Results on November 12, 2021 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform that has the potential to improve the absorption of many drugs...
Oct 29, 2021 06:50 am ET
PLx Pharma Inc. Provides VAZALORE Launch Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform that has the potential to improve the absorption of many drugs...
Oct 14, 2021 01:27 pm ET
PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease; PLx’s VAZALORE Specifically Indicated for Secondary Prevention
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Sep 09, 2021 06:50 am ET
PLx Pharma Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Aug 26, 2021 06:00 am ET
PLx Pharma Inc.’s VAZALORE™ Now on Shelves; National Media Campaign Launches Today
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Aug 06, 2021 06:50 am ET
PLx Pharma Inc. Reports Second Quarter 2021 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Aug 02, 2021 04:30 pm ET
PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Jul 26, 2021 04:30 pm ET
PLx Pharma Inc.’s VAZALORE to Launch in Over 2,400 Rite Aid Stores in August
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Jul 22, 2021 04:30 pm ET
PLx Pharma Inc. to Discuss 2021 Second Quarter Financial Results on August 6, 2021 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Jul 20, 2021 08:30 am ET
Thinking about buying stock in Neurobo Pharmaceuticals, Xenetic Biosciences, Amneal Pharmaceuticals, PLx Pharma, or Orbital Energy Group?
NEW YORK, July 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NRBO, XBIO, AMRX, PLXP, and OEG.
Jul 19, 2021 05:00 pm ET
PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Jul 12, 2021 04:30 pm ET
PLx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Jun 09, 2021 04:30 pm ET
PLx Pharma Inc. to Present at Upcoming Healthcare Industry Conferences
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
May 14, 2021 06:50 am ET
PLx Pharma Inc. Reports First Quarter 2021 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
May 03, 2021 04:30 pm ET
PLx Pharma Inc. to Discuss 2021 First Quarter Financial Results on May 14, 2021 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products, with its...
Mar 12, 2021 06:50 am ET
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Mar 11, 2021 05:00 pm ET
PLx Pharma Inc. to Present at the Oppenheimer 31st Annual Healthcare Conference
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead...
Mar 04, 2021 05:30 pm ET
PLx Pharma Inc. to Discuss 2020 Fourth Quarter Financial Results on March 12, 2021 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products,...
Mar 03, 2021 08:48 am ET
PLx Pharma Inc. Prices $63 Million Underwritten Public Offering of Common Stock
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products,...
Mar 02, 2021 04:05 pm ET
PLx Pharma Inc. Announces Proposed Public Offering of Common Stock
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products,...
Mar 01, 2021 06:50 am ET
PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer...
Nov 16, 2020 04:05 pm ET
PLx Pharma Inc. Reports Third Quarter 2020 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its...
Nov 16, 2020 04:01 pm ET
PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration
PLx Pharma Inc. (NASDAQ: PLXP), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, announced today that two chemistry...
Nov 12, 2020 05:30 pm ET
PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,...
Nov 03, 2020 06:50 am ET
PLx Pharma Inc. to Discuss 2020 Third Quarter Financial Results on November 13, 2020 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,...
Sep 14, 2020 04:30 pm ET
PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,...
Aug 14, 2020 06:50 am ET
PLx Pharma Inc. Reports Second Quarter 2020 Results and Provides Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,...
Aug 05, 2020 04:30 pm ET
PLx Pharma Inc. to Discuss 2020 Second Quarter Financial Results on August 14, 2020 Conference Call and Provide Business Update
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,...
May 18, 2020 04:30 pm ET
PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
May 15, 2020 06:50 am ET
PLx Pharma Inc. Reports First Quarter 2020 Results
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
May 04, 2020 06:50 am ET
PLx Pharma Inc. to Discuss 2020 First Quarter Financial Results on May 15, 2020 Conference Call
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,...
Mar 13, 2020 06:50 am ET
PLx Pharma Inc. Reports Fourth Quarter 2019 Results and Provides Regulatory Update on VAZALORE
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Mar 03, 2020 06:50 am ET
PLx Pharma Inc. to Discuss 2019 Fourth Quarter and Full Year Financial Results on March 13, 2020 Conference Call
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard™ delivery system, announced today that the Company...
Feb 21, 2020 06:50 am ET
PLx Pharma Inc. Presents Original Abstract and Simultaneous Publication of its Novel, Liquid-Filled Capsule Aspirin Formulation at the 2020 International Stroke Conference
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard™ delivery system, announced today the presentation of...
Jan 07, 2020 06:50 am ET
PLx Pharma Inc. to Present at Biotech Showcase 2020
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Jan 06, 2020 06:50 am ET
PLx Pharma Inc. Provides Regulatory Update on VAZALORE
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Nov 08, 2019 06:50 am ET
PLx Pharma Inc. Reports Third Quarter 2019 Results
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Oct 28, 2019 06:50 am ET
PLx Pharma Inc. to Discuss 2019 Third Quarter Financial Results on November 8, 2019 Conference Call
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Sep 03, 2019 06:50 am ET
PLx Pharma Inc. Presents Moderated Abstract and Simultaneous Publication on the Pharmacokinetic and Pharmacodynamics (PK/PD) Properties of its Novel, Liquid Aspirin Formulation at the 2019 European So
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard™ delivery system announced today the presentation of a...
Aug 28, 2019 04:30 pm ET
PLx Pharma Inc. to Present at Janney Healthcare Conference 2019 on September 10
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Aug 09, 2019 06:50 am ET
PLx Pharma Inc. Reports Second Quarter 2019 Results
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Jul 30, 2019 04:30 pm ET
PLx Pharma Inc. to Discuss 2019 Second Quarter Financial Results on August 9, 2019 Conference Call
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Jun 19, 2019 07:00 am ET
PLx Pharma on Track for VAZALORE Regulatory Pathway
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Jun 10, 2019 04:30 pm ET
PLx Pharma Inc. to Present at JMP Securities Life Sciences Conference
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
May 10, 2019 06:50 am ET
PLx Pharma Inc. Reports First Quarter 2019 Results
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
May 02, 2019 06:50 am ET
PLx Pharma Inc. to Discuss 2019 First Quarter Financial Results on May 10, 2019 Conference Call
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Mar 08, 2019 06:50 am ET
PLx Pharma Inc. Reports Fourth Quarter 2018 Results
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer...
Feb 25, 2019 04:30 pm ET
PLx Pharma Inc. to Discuss 2018 Fourth Quarter and Full Year Financial Results on March 8, 2019 Conference Call
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Feb 20, 2019 04:55 pm ET
PLx Pharma Inc. Announces Completion of $15 Million Convertible Preferred Stock Financing
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Feb 14, 2019 11:30 am ET
PLx Pharma Inc. Announces Adjournment of Special Meeting of Stockholders
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Dec 20, 2018 07:32 pm ET
PLx Pharma Inc. Announces $15 Million Convertible Preferred Stock Financing
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Dec 18, 2018 04:30 pm ET
PLx Pharma Inc. to Present at Biotech Showcase 2019
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Nov 09, 2018 06:50 am ET
PLx Pharma Inc. Reports Third Quarter 2018 Results
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Nov 01, 2018 07:00 am ET
PLx Pharma Inc. to Discuss 2018 Third Quarter Financial Results on November 9, 2018 Conference Call
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Sep 10, 2018 04:30 pm ET
PLx Pharma Inc. to Present at Janney Healthcare Conference on September 18
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Aug 10, 2018 07:00 am ET
PLx Pharma Inc. Reports Second Quarter 2018 Results
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together as “Vazalore”™), announced...
Jun 11, 2018 04:30 pm ET
PLx Pharma Inc. to Present at JMP Securities Life Sciences Conference
PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced...
May 11, 2018 06:50 am ET
PLx Pharma Inc. Reports First Quarter 2018 Results
PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced...
Mar 23, 2018 06:50 am ET
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2017 Results
HOUSTON, March 23, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™),...
Mar 15, 2018 04:30 pm ET
PLx Pharma Inc. to Discuss 2017 Fourth Quarter and Full Year Financial Results on March 23, 2018 Conference Call
HOUSTON, March 15, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™),...
Nov 09, 2017 04:30 pm ET
PLx Pharma Inc. Reports Third Quarter 2017 Results
HOUSTON, Nov. 09, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™),...
Nov 09, 2017 04:30 pm ET
PLx Pharma Inc. Reports Third Quarter 2017 Results
HOUSTON, Nov. 09, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today its financial and certain operational results for the three- and nine-month periods ended September 30, 2017....
Nov 02, 2017 08:00 am ET
PLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference Call
HOUSTON, Nov. 02, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™),...
Sep 18, 2017 04:30 pm ET
PLx Pharma Present at the Sidoti & Company Fall 2017 Conference
HOUSTON, Sept. 18, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present at the Sidoti & Company Fall 2017 Conference as follows:...
Jun 14, 2017 04:30 pm ET
PLx Pharma Inc. Announces Closing of Registered Direct Offering
HOUSTON, June 14, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced today that it has closed its previously announced registered direct offering of 2,646,091 shares of common stock at an offering price per share of $6.875, as well as a concurrent private placement of warrants to purchase up to an equivalent number of shares of common stock with an exercise price of $7.50 p...
May 01, 2017 07:00 am ET
PLx Pharma Appoints Michael J. Dillon as Vice President, Sales and Marketing
HOUSTON, May 01, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced the appointment of industry veteran and commercial leader, Michael J. Dillon as Vice President, Sales and Marketing effective today....
Apr 19, 2017 07:21 pm ET
PLx Pharma and Dipexium Pharmaceuticals Complete Merger
HOUSTON, April 19, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products: Aspertec 325 mg and Aspertec 81 mg (referred to together as “Aspertec”™), has completed its previously announced merger with Dipexium Pharmaceuticals, Inc. (“Dipexium”), effective as of April 19, 2017. The combined company—which changed its name to PLx Pharma Inc. immediately following the merger—will begin trading on the NASDAQ Capital Market under the symbol “PLXP” on April 20, 2017....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.